Bryan Johnson· Author
Moreover, loss-of-function mutations in PCSK9 lead to a 28% reduction in LDL and correlate to an 88% reduction in coronary heart disease.
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
Moreover, loss-of-function mutations in PCSK9 lead to a 28% reduction in LDL and correlate to an 88% reduction in coronary heart disease.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
indeed people have very low levels of LDL like let's say they have a there's a condition known as a beta lipoprotein emia where they basically have nearly none and those people will just not have atherosclerosis and people who have familial hypo beta lipoprotein emia and those people just have extremely low levels right almost as if they have a natural pcsk9 and have actually there are people who have pcsk9 loss-of-function genes for example all of these people have super low levels and they have super low levels of atherosclerosis
we have genetic mutations that have an April B of like 10 to 15. um these are people with pcsk9 loss of function mutations which is How We Invented the pcsk9 medications like rapatha and problems and now in glycerin um people with knock knocked out pcsk9s or the pcsk9 gene doesn't function they have an LDL cholesterol like 10 15 maybe 20 at the most and they live the longest and they live the longest atherosclerosis free sure at as they get older they'll probably get something else obviously everyone has to die but we know that they at least won't have atherosclerosis
you've explained now why a pcsk9 inhibitor the drugs we're talking about are so effective in lowering apob because they're basically mimicking the most extreme loss of function of this gene you're taking away that protein that does those three things to reduce lp ldl clearance
you know we know that individuals with pcsk9 genetic mutations that were loss of function these individuals had very low ldls and very low risk of cardiovascular disease of a lifetime
the actual Gene that you were mentioning the pcsk9 right so when you were talking about we have pharmacological interventions that do very nicely lower apob one of them is PCS can9 Inhibitors exactly came right out of Helen Hobs observation